Health Canada approved Tagrisso (osimertinib) for patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer who have progressed on or after EGFR tyrosine kinase inhibitor therapy. Tagrisso, sponsored by AstraZeneca Canada, was granted Notice of Compliance with Conditions, based on promising evidence of clinical efficacy data, pending the results of additional...
In this week's episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher, and Sara Willa Ernst, reporter, go on a trip into the world of federal health policy surrounding psychedelic medicine.
